Cargando…
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
BACKGROUND: The allergic phenotype is responsible for more than 50% of severe asthma cases. In a stepwise approach, add-on treatments such as anti-IgE are used for severe allergic asthma (SAA). This study was aimed to describe the real-world effectiveness of omalizumab in adult and pediatric patient...
Autores principales: | Torres-Duque, Carlos A., Ocampo-Gómez, Jaime, Castillo, Mauricio Morales, Cano-Rosales, Diana, Giraldo-Montoya, Ángela, Rodríguez, Freddy, Palacios-Ortega, Isabel, Durán-Silva, Mauricio, Reynales, Humberto, García, Elizabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703713/ https://www.ncbi.nlm.nih.gov/pubmed/36437461 http://dx.doi.org/10.1186/s12890-022-02246-x |
Ejemplares similares
-
Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018) -
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017) -
Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia
por: García-Gómez, Elizabeth, et al.
Publicado: (2022) -
Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008) -
Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)